Provectus Biopharmaceuticals (PVCT) 10-Q12 Nov 132013 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013
Document Information [Line Items]	'
Document Type	'10-Q
Amendment Flag	'false
Document Period End Date	30-Sep-13
Document Fiscal Year Focus	'2013
Document Fiscal Period Focus	'Q3
Entity Registrant Name	'PROVECTUS PHARMACEUTICALS INC
Entity Central Index Key	'0000315545
Current Fiscal Year End Date	'--12-31
Entity Filer Category	'Accelerated Filer
Entity Common Stock, Shares Outstanding	139,974,331
8% Convertible Preferred Stock [Member]	'
Document Information [Line Items]	'
Entity Common Stock, Shares Outstanding	746,666
Series A 8% Convertible Preferred Stock [Member]	'
Document Information [Line Items]	'
Entity Common Stock, Shares Outstanding	2,958,334

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets	'	'
Cash and cash equivalents	$8,253,591	$1,221,701
Prepaid expenses and other current assets	45,284	'
Total Current Assets	8,298,875	1,221,701
Equipment and furnishings, less accumulated depreciation of $427,615 and $422,965	31,829	29,829
Patents, net of amortization of $7,292,837 and $6,789,497, respectively	4,422,608	4,925,948
Other assets	27,000	27,000
Total Assets	12,780,312	6,204,478
Current Liabilities	'	'
Accounts payable - trade	202,464	243,435
Accrued compensation and payroll taxes	98,720	'
Accrued consulting expense	61,282	61,283
Other accrued expenses	180,001	206,706
Total Current Liabilities	542,467	511,424
Long-Term Liability	'	'
Warrant liability	3,514,622	1,299,570
Total Liabilities	4,057,089	1,810,994
Stockholders' Equity	'	'
Preferred stock; par value $.001 per share; 25,000,000 shares authorized including; 8% convertible preferred stock, 746,666 and 2,478,185 shares issued and outstanding, respectively, liquidation preference $0.75 (in aggregate $570,585 and $1,896,117, respectively); Series A 8% convertible preferred stock, 2,958,334 shares issued and outstanding in 2013, liquidation preference $0.75 (in aggregate $2,246,855)	3,705	2,478
Common stock; par value $.001 per share; 250,000,000 authorized; 139,974,331 and 118,427,925 shares issued and outstanding, respectively	139,974	118,428
Paid-in capital	138,032,870	122,625,654
Deficit accumulated during the development stage	-129,453,326	-118,353,076
Total Stockholders' Equity	8,723,223	4,393,484
Total Liabilities and Stockholders' Equity	$12,780,312	$6,204,478

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accumulated depreciation on equipment and furnishings	$427,615	$422,965
Amortization on patents	7,292,837	6,789,497
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	25,000,000	25,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	139,974,331	118,427,925
Common stock, shares outstanding	139,974,331	118,427,925
8% Convertible Preferred Stock [Member]	'	'
Preferred stock, shares issued	746,666	2,478,185
Preferred stock, shares outstanding	746,666	2,478,185
Preferred stock, liquidation preference per share	$0.75	$0.75
Aggregate liquidation preference	570,585	1,896,117
Convertible preferred stock	8.00%	8.00%
Series A 8% Convertible Preferred Stock [Member]	'	'
Preferred stock, shares issued	2,958,334	'
Preferred stock, shares outstanding	2,958,334	'
Preferred stock, liquidation preference per share	$0.75	$0.75
Aggregate liquidation preference	$2,246,855	$2,246,855
Convertible preferred stock	8.00%	8.00%

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended		140 Months Ended
Condensed Consolidated Statements of Operations (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Revenues	'	'	'	'	'
OTC product revenue	'	'	'	'	$25,648
Medical device revenue	'	'	'	'	14,109
Total revenues	'	'	'	'	39,757
Cost of sales	'	'	'	'	15,216
Gross profit	'	'	'	'	24,541
Operating expenses	'	'	'	'	'
Research and development	1,296,654	1,129,921	2,815,519	4,352,940	45,914,372
General and administrative	2,185,756	2,296,637	6,864,865	7,228,225	73,050,754
Amortization	167,780	167,780	503,340	503,340	7,292,837
Total operating loss	'	-3,594,338	-10,183,724	-12,084,505	-126,233,422
Gain on sale of fixed assets	'	'	'	'	55,075
Loss on extinguishment of debt	'	'	'	'	-825,867
Investment income	293	310	576	1,325	653,793
(Loss) gain on change in fair value of warrant liability	-902,798	1,246,917	-917,102	1,435,898	4,995,099
Net interest expense	'	'	'	'	-8,098,004
Net loss	-4,552,695	-2,347,111	-11,100,250	-10,647,282	-129,453,326
Dividends on preferred stock	-38,690	-43,884	-1,188,648	-145,709	-12,026,710
Net loss applicable to common shareholders	($4,591,385)	($2,390,995)	($12,288,898)	($10,792,991)	($141,480,036)
Basic and diluted loss per common share	($0.03)	($0.02)	($0.10)	($0.10)	'
Weighted average number of common shares outstanding - basic and diluted	131,573,656	113,166,988	126,503,388	112,073,836	'

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Paid in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Jan. 17, 2002	'	'	'	'	'
Issuance to founding shareholders	'	'	$6,000	($6,000)	'
Issuance to founding shareholders, shares	'	'	6,000,000	'	'
Sale of stock	25,000	'	50	24,950	'
Sale of stock, shares	'	'	50,000	'	'
Issuance of stock to employees	932,000	'	510	931,490	'
Issuance of stock to employees, shares	'	'	510,000	'	'
Issuance of stock for services	360,000	'	120	359,880	'
Issuance of stock for services, shares	'	'	120,000	'	'
Net loss	-1,316,198	'	'	'	-1,316,198
Ending Balance at Apr. 23, 2002	802	'	6,680	1,310,320	-1,316,198
Ending Balance, shares at Apr. 23, 2002	'	'	6,680,000	'	'
Shares issued in reverse merger	-3,645	'	266	-3,911	'
Shares issued in reverse merger, shares	'	'	265,763	'	'
Purchase and retirement of stock	-48,000	'	-400	-47,600	'
Purchase and retirement of stock, shares	'	'	-400,000	'	'
Stock issued for acquisition of Valley Pharmaceuticals	12,226,320	'	500	12,225,820	'
Stock issued for acquisition of Valley Pharmaceuticals, shares	'	'	500,007	'	'
Exercise of warrants	453	'	453	'	'
Issuance of stock for services	5,144,000	'	1,900	5,142,100	'
Exercise of warrants, shares	'	'	452,919	'	'
Warrants issued in connection with convertible debt	126,587	'	'	126,587	'
Issuance of stock for services, shares	'	'	1,900,000	'	'
Stock and warrants issued for acquisition of Pure-ific	27,000	'	25	26,975	'
Stock and warrants issued for acquisition of Pure-ific, shares	'	'	25,000	'	'
Net loss	-5,749,937	'	'	'	-5,749,937
Ending Balance at Dec. 31, 2002	11,723,580	'	9,424	18,780,291	-7,066,135
Ending Balance, shares at Dec. 31, 2002	'	'	9,423,689	'	'
Stock to be issued for services	281,500	'	'	281,500	'
Issuance of warrants for services	145,479	'	'	145,479	'
Issuance of stock pursuant to Regulation S	380,347	'	680	379,667	'
Issuance of stock pursuant to Regulation S, shares	'	'	679,820	'	'
Issuance of stock for services	239,800	'	764	239,036	'
Issuance of stock for services, shares	'	'	764,000	'	'
Employee compensation from stock options	34,659	'	'	34,659	'
Beneficial conversion related to convertible debt	601,000	'	'	601,000	'
Net loss	-3,155,313	'	'	'	-3,155,313
Ending Balance at Dec. 31, 2003	10,251,052	'	10,868	20,461,632	-10,221,448
Ending Balance, shares at Dec. 31, 2003	'	'	10,867,509	'	'
Issuance of warrants for services	495,480	'	'	495,480	'
Issuance of stock pursuant to Regulation S	793,137	'	2,469	790,668	'
Issuance of stock pursuant to Regulation S, shares	'	'	2,469,723	'	'
Exercise of warrants	5,000	'	133	4,867	'
Issuance of stock for services	449,923	'	734	449,190	'
Exercise of warrants, shares	'	'	132,608	'	'
Issuance of stock for services, shares	'	'	733,872	'	'
Employee compensation from stock options	15,612	'	'	15,612	'
Issuance of convertible debt with warrants	105,250	'	'	105,250	'
Issuance of stock and warrants pursuant to Regulation D	1,288,861	'	1,930	1,286,930	'
Issuance of stock and warrants pursuant to Regulation D, shares	'	'	1,930,164	'	'
Beneficial conversion related to convertible debt	360,256	'	'	360,256	'
Repurchase of beneficial conversion feature	-258,345	'	'	-258,345	'
Net loss	-4,344,525	'	'	'	-4,344,525
Ending Balance at Dec. 31, 2004	9,161,701	'	16,134	23,711,540	-14,565,973
Ending Balance, shares at Dec. 31, 2004	'	'	16,133,876	'	'
Issuance of stock for interest payable	196,031	'	264	195,767	'
Issuance of stock for interest payable, shares	'	'	263,721	'	'
Issuance of warrants for services	1,534,405	'	'	1,534,405	'
Issuance of warrants for contractual obligations	985,010	'	'	985,010	'
Exercise of warrants and stock options	1,439,795	'	1,572	1,438,223	'
Exercise of warrants and stock options, shares	'	'	1,571,849	'	'
Issuance of stock for services	152,285	'	227	152,058	'
Issuance of stock for services, shares	'	'	226,733	'	'
Employee compensation from stock options	15,752	'	'	15,752	'
Issuance of convertible debt with warrants	1,574,900	'	'	1,574,900	'
Issuance of stock and warrants pursuant to Regulation D	6,513,176	'	6,221	6,506,955	'
Issuance of stock and warrants pursuant to Regulation D, shares	'	'	6,221,257	'	'
Beneficial conversion related to interest expense	39,529	'	'	39,529	'
Preferred stock/Debt conversions into common stock	3,049,362	'	3,405	3,045,957	'
Preferred stock/Debt conversions into common stock, shares	'	'	3,405,541	'	'
Beneficial conversion related to convertible debt	1,633,176	'	'	1,633,176	'
Repurchase of beneficial conversion feature	-144,128	'	'	-144,128	'
Net loss	-11,763,853	'	'	'	-11,763,853
Ending Balance at Dec. 31, 2005	14,387,141	'	27,823	40,689,144	-26,329,826
Ending Balance, shares at Dec. 31, 2005	'	'	27,822,977	'	'
Issuance of stock for interest payable	183,596	'	195	183,401	'
Issuance of stock for interest payable, shares	'	'	194,327	'	'
Issuance of warrants for services	370,023	'	'	370,023	'
Exercise of warrants and stock options	1,189,816	'	1,246	1,188,570	'
Exercise of warrants and stock options, shares	'	'	1,245,809	'	'
Issuance of stock for services	676,743	'	719	676,024	'
Issuance of stock for services, shares	'	'	719,246	'	'
Employee compensation from stock options	1,862,456	'	'	1,862,456	'
Issuance of stock and warrants pursuant to Regulation D	4,130,421	'	10,092	4,120,329	'
Issuance of stock and warrants pursuant to Regulation D, shares	'	'	10,092,495	'	'
Beneficial conversion related to interest expense	16,447	'	'	16,447	'
Preferred stock/Debt conversions into common stock	1,576,336	'	2,377	1,573,959	'
Preferred stock/Debt conversions into common stock, shares	'	'	2,377,512	'	'
Net loss	-8,870,579	'	'	'	-8,870,579
Ending Balance at Dec. 31, 2006	15,522,400	'	42,452	50,680,353	-35,200,405
Ending Balance, shares at Dec. 31, 2006	'	'	42,452,366	'	'
Issuance of stock for interest payable	1,258	'	1	1,257	'
Issuance of stock for interest payable, shares	'	'	1,141	'	'
Issuance of warrants for services	472,635	'	'	472,635	'
Exercise of warrants and stock options	3,985,641	'	3,929	3,981,712	'
Exercise of warrants and stock options, shares	'	'	3,928,957	'	'
Issuance of stock for services	298,950	'	150	298,800	'
Issuance of stock for services, shares	'	'	150,000	'	'
Employee compensation from stock options	2,340,619	'	'	2,340,619	'
Issuance of stock and warrants pursuant to Regulation D	1,848,138	'	2,377	1,845,761	'
Issuance of stock and warrants pursuant to Regulation D, shares	'	'	2,376,817	'	'
Preferred stock/Debt conversions into common stock	367,500	'	490	367,010	'
Preferred stock/Debt conversions into common stock, shares	'	'	490,000	'	'
Net loss	-10,005,631	'	'	'	-10,005,631
Ending Balance at Dec. 31, 2007	14,831,510	'	49,399	59,988,147	-45,206,036
Ending Balance, shares at Dec. 31, 2007	'	'	49,399,281	'	'
Issuance of warrants for services	517,820	'	'	517,820	'
Exercise of warrants and stock options	2,639,711	'	3,268	2,636,443	'
Exercise of warrants and stock options, shares	'	'	3,267,795	'	'
Issuance of stock for services	390,000	'	350	389,650	'
Issuance of stock for services, shares	'	'	350,000	'	'
Employee compensation from stock options	1,946,066	'	'	1,946,066	'
Net loss	-10,269,571	'	'	'	-10,269,571
Ending Balance at Dec. 31, 2008	10,055,536	'	53,017	65,478,126	-55,475,607
Ending Balance, shares at Dec. 31, 2008	'	'	53,017,076	'	'
Issuance of warrants for services	1,064,210	'	'	1,064,210	'
Exercise of warrants and stock options	2,524,453	'	3,480	2,520,973	'
Exercise of warrants and stock options, shares	'	'	3,480,485	'	'
Issuance of stock for services	695,000	'	796	694,204	'
Issuance of stock for services, shares	'	'	796,012	'	'
Employee compensation from stock options	870,937	'	'	870,937	'
Issuance of stock and warrants pursuant to Regulation D	6,518,688	'	10,117	6,508,571	'
Issuance of stock and warrants pursuant to Regulation D, shares	'	'	10,116,653	'	'
Net loss	-12,322,314	'	'	'	-12,322,314
Ending Balance at Dec. 31, 2009	9,406,510	'	67,410	77,137,021	-67,797,921
Ending Balance, shares at Dec. 31, 2009	'	'	67,410,226	'	'
Issuance of warrants for services	1,141,593	'	'	1,141,593	'
Issuance of stock pursuant to Regulation S	419,250	'	559	418,691	'
Exercise of warrants and stock options	3,103,680	'	3,491	3,100,189	'
Issuance of stock pursuant to Regulation S, shares	'	'	559,000	'	'
Exercise of warrants and stock options, shares	'	'	3,491,014	'	'
Issuance of common stock and warrants pursuant to Regulation D	6,346,989	'	11,169	6,335,820	'
Issuance of common stock and warrants pursuant to Regulation D, shares	'	'	11,168,067	'	'
Issuance of preferred stock and warrants pursuant to Regulation D	4,217,390	13,283	'	4,204,107	'
Issuance of stock for services	856,613	'	776	855,837	'
Issuance of preferred stock and warrants pursuant to Regulation D, shares	'	13,283,324	'	'	'
Issuance of stock for services, shares	'	'	776,250	'	'
Employee compensation from stock options	3,759,650	'	'	3,759,650	'
Preferred stock/Debt conversions into common stock	'	-7,893	7,893	'	'
Preferred stock/Debt conversions into common stock, shares	'	-7,893,326	7,893,326	'	'
Net loss	-18,552,102	'	'	'	-18,552,102
Ending Balance at Dec. 31, 2010	10,699,573	5,390	91,298	96,952,908	-86,350,023
Ending Balance, shares at Dec. 31, 2010	'	5,389,998	91,297,883	'	'
Issuance of warrants for services	945,116	'	'	945,116	'
Exercise of warrants and stock options	6,623,311	'	7,185	6,616,126	'
Exercise of warrants and stock options, shares	'	'	7,185,522	'	'
Issuance of common stock and warrants pursuant to Regulation D	7,041,239	'	9,905	7,031,334	'
Sale of non-controlling interest in Pure-ific Corporation and warrants	443,500	'	'	443,500	'
Issuance of common stock and warrants pursuant to Regulation D, shares	'	'	9,905,062	'	'
Issuance of stock for services	332,750	'	350	332,400	'
Issuance of stock for services, shares	'	'	350,000	'	'
Employee compensation from stock options	3,368,950	'	'	3,368,950	'
Preferred stock/Debt conversions into common stock	'	-1,859	1,859	'	'
Preferred stock/Debt conversions into common stock, shares	'	-1,858,333	1,858,331	'	'
Net loss	-19,434,699	'	'	'	-19,434,699
Ending Balance at Dec. 31, 2011	10,019,740	3,531	110,597	115,690,334	-105,784,722
Ending Balance, shares at Dec. 31, 2011	'	3,531,665	110,596,798	'	'
Issuance of warrants for services	1,512,026	'	'	1,512,026	'
Issuance of common stock and warrants pursuant to Regulation D	4,790,544	'	6,228	4,784,316	'
Issuance of common stock and warrants pursuant to Regulation D, shares	'	'	6,227,647	'	'
Issuance of stock for services	456,500	'	550	455,950	'
Issuance of stock for services, shares	'	'	550,000	'	'
Employee compensation from stock options	183,028	'	'	183,028	'
Preferred stock/Debt conversions into common stock	'	-1,053	1,053	'	'
Preferred stock/Debt conversions into common stock, shares	'	-1,053,480	1,053,480	'	'
Net loss	-12,568,354	'	'	'	-12,568,354
Ending Balance at Dec. 31, 2012	4,393,484	2,478	118,428	122,625,654	-118,353,076
Ending Balance, shares at Dec. 31, 2012	'	2,478,185	118,427,925	'	'
Issuance of warrants for services	1,527,518	'	'	1,527,518	'
Exercise of warrants and stock options	21,000	'	44	20,956	'
Exercise of warrants and stock options, shares	'	'	43,750	'	'
Issuance of common stock and warrants pursuant to Regulation D	12,204,174	'	18,854	12,185,320	'
Issuance of common stock and warrants pursuant to Regulation D, shares	'	'	18,854,470	'	'
Issuance of preferred stock and warrants pursuant to Regulation D	1,252,050	3,400	'	1,248,650	'
Issuance of stock for services	149,500	'	475	311,525	'
Issuance of preferred stock and warrants pursuant to Regulation D, shares	'	3,400,001	'	'	'
Issuance of stock for services, shares	'	'	475,000	'	'
Employee compensation from stock options	142,310	'	'	142,310	'
Dividends on preferred stock	-29,063	'	'	-29,063	'
Preferred stock/Debt conversions into common stock	-29,063	-2,173	2,173	-29,063	'
Preferred stock/Debt conversions into common stock, shares	'	-2,173,186	2,173,186	'	'
Net loss	-11,100,250	'	'	'	-11,100,250
Ending Balance at Sep. 30, 2013	$8,723,223	$3,705	$139,974	$138,032,870	($129,453,326)
Ending Balance, shares at Sep. 30, 2013	'	3,705,000	139,974,331	'	'

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flow (USD $)	9 Months Ended		140 Months Ended
Condensed Consolidated Statements of Cash Flow (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash Flows From Operating Activities	'	'	'
Net loss	($11,100,250)	($10,647,282)	($129,453,326)
Adjustments to reconcile net loss to net cash used in operating activities	'	'	'
Depreciation	4,650	4,579	450,616
Amortization of patents	503,340	503,340	7,292,837
Amortization of original issue discount	'	'	3,845,721
Amortization of commitment fee	'	'	310,866
Amortization of prepaid consultant expense	'	'	1,295,226
Amortization of deferred loan costs	'	'	2,261,584
Accretion of United States Treasury Bills	'	'	-373,295
Loss on extinguishment of debt	'	'	825,867
Loss on exercise of warrants	'	'	236,146
Beneficial conversion of convertible interest	'	'	55,976
Convertible interest	'	'	389,950
Compensation through issuance of stock options	142,310	183,028	14,540,039
Compensation through issuance of stock	'	'	932,000
Issuance of stock for services	312,000	409,250	9,365,511
Issuance of warrants for services	1,527,518	1,381,329	7,724,087
Issuance of warrants for contractual obligations	'	'	985,010
Gain on sale of equipment	'	'	-55,075
Loss (gain) on change in fair value of warrant liability	917,102	-1,435,898	-4,995,099
Change in assets and liabilities	'	'	'
Prepaid expenses and other current assets	-45,284	-16,284	-45,284
Accounts payable	-40,971	179,513	198,819
Accrued expenses	72,014	1,512,859	489,633
Net cash used in operating activities	-7,707,571	-7,925,566	-83,722,191
Cash Flows From Investing Activities	'	'	'
Proceeds from sale of fixed assets	'	'	180,075
Capital expenditures	-6,650	-15,885	-96,570
Proceeds from sales of investments	'	'	37,010,481
Purchases of investments	'	'	-36,637,186
Net cash (used in) provided by investing activities	-6,650	-15,885	456,800
Cash Flows From Financing Activities	'	'	'
Net proceeds from loans from stockholder	'	'	174,000
Proceeds from convertible debt	'	'	6,706,795
Net proceeds from sales of preferred stock and warrants	2,550,000	'	11,458,131
Net proceeds from sales of common stock and warrants	12,204,174	2,077,796	55,018,695
Proceeds from exercises of warrants and stock options	21,000	'	21,099,014
Cash paid for preferred dividends	-29,063	'	-29,063
Cash paid to retire convertible debt	'	'	-2,385,959
Cash paid for deferred loan costs	'	'	-747,612
Premium paid on extinguishments of debt	'	'	-170,519
Purchase and retirement of common stock	'	'	-48,000
Net proceeds from sale of non-controlling interest in Pure-ific Corporation	'	'	443,500
Net cash provided by financing activities	14,746,111	2,077,796	91,518,982
Net change in cash and cash equivalents	7,031,890	-5,863,655	8,253,591
Cash and cash equivalents, at beginning of period	1,221,701	7,705,773	'
Cash and cash equivalents, at end of period	$8,253,591	$1,842,118	$8,253,591

Basis_of_Presentation

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	1. Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ended December 31, 2013. The Company has evaluated subsequent events through the date the condensed consolidated financial statements were issued.

Recapitalization_and_Merger

Recapitalization and Merger	9 Months Ended
Recapitalization and Merger	Sep. 30, 2013
Business Combinations [Abstract]	'
Recapitalization and Merger	'
	2. Recapitalization and Merger
	Provectus Pharmaceuticals, Inc., formerly known as “Provectus Pharmaceutical, Inc.” and “SPM Group, Inc.,” was incorporated under Colorado law on May 1, 1978. SPM Group ceased operations in 1991, and became a development-stage company effective January 1, 1992, with the new corporate purpose of seeking out acquisitions of properties, businesses, or merger candidates, without limitation as to the nature of the business operations or geographic location of the acquisition candidate.
	On April 1, 2002, SPM Group changed its name to “Provectus Pharmaceutical, Inc.” and reincorporated in Nevada in preparation for a transaction with Provectus Pharmaceuticals, Inc., a privately-held Tennessee corporation (“PPI”). On April 23, 2002, an Agreement and Plan of Reorganization between Provectus Pharmaceutical and PPI was approved by the written consent of a majority of the outstanding shares of Provectus Pharmaceutical. As a result, Provectus Pharmaceuticals, Inc. issued 6,680,000 shares of common stock in exchange for all of the issued and outstanding shares of PPI. As part of the acquisition, Provectus Pharmaceutical changed its name to “Provectus Pharmaceuticals, Inc.” and PPI became a wholly-owned subsidiary of Provectus. This transaction was recorded as a recapitalization of PPI.
	On November 19, 2002, the Company acquired Valley Pharmaceuticals, Inc., a privately-held Tennessee corporation formerly known as Photogen, Inc., by merging PPI with and into Valley and naming the surviving corporation “Xantech Pharmaceuticals, Inc.” Photogen, Inc. was separated from Photogen Technologies, Inc. in a non-pro-rata split-off to some of its shareholders. The assets of Photogen, Inc. consisted primarily of the equipment and intangibles related to its therapeutic activity and were recorded at their fair value. The majority shareholders of Valley were also the majority shareholders of Provectus. Valley had no revenues prior to the transaction with the Company. By acquiring Valley, the Company acquired its intellectual property, including issued U.S. patents and patentable inventions.

Basic_and_Diluted_Loss_Per_Com

Basic and Diluted Loss Per Common Share	9 Months Ended
Basic and Diluted Loss Per Common Share	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Basic and Diluted Loss Per Common Share	'
	3. Basic and Diluted Loss Per Common Share
	Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Loss per share excludes the impact of outstanding options and warrants and convertible preferred stock as they are antidilutive. Potential common shares excluded from the calculation at September 30, 2013 and 2012, respectively, relate to 66,238,507 and 26,042,116 from warrants, 15,322,206 and 15,140,956 from options, and 3,705,000 and 2,941,665 from convertible preferred shares.

Equity_Transactions

Equity Transactions	9 Months Ended
Equity Transactions	Sep. 30, 2013
Text Block [Abstract]	'
Equity Transactions	'
	4. Equity Transactions
	(a) During the three months ended March 31, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $48,750. During the three months ended March 31, 2012, the Company issued 175,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $160,000.
	During the three months ended June 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $49,500. During the three months ended June 30, 2012, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $64,500.
	During the three months ended September 30, 2013, the Company issued 75,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $51,250. During the three months ended September 30, 2012, the Company issued 225,000 shares of common stock to consultants in exchange for services. Consulting costs charged to operations were $184,750.
	As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model.

	(b) During the three months ended March 31, 2013, the Company issued 1,924,973 warrants to consultants in exchange for services. Consulting costs charged to operations were $409,640. During the three months ended March 31, 2013, 859,833 warrants were forfeited. During the three months ended March 31, 2012, the Company issued 1,003,000 warrants to consultants in exchange for services. Consulting costs charged to operations were $475,668. During the three months ended March 31, 2012, 1,500 warrants were forfeited.
	During the three months ended June 30, 2013, the Company issued 2,605,000 warrants to consultants in exchange for services. Consulting costs charged to operations were $931,655. During the three months ended June 30, 2013, 1,051,500 warrants were forfeited. During the three months ended June 30, 2012, the Company issued 454,500 warrants to consultants in exchange for services. Consulting costs charged to operations were $183,908. During the three months ended June 30, 2012, 4,368,644 warrants were forfeited.
	During the three months ended September 30, 2013, the Company issued 442,000 warrants to consultants in exchange for services. Consulting costs charged to operations were $186,223. During the three months ended September 30, 2013, 136,500 warrants were forfeited. During the three months ended September 30, 2012, the Company issued 1,732,135 warrants to consultants in exchange for services. Consulting costs charged to operations were $721,753. During the three months ended September 30, 2012, 122,833 warrants were forfeited.
	As the fair market value of these services was not readily determinable, these services were valued based on the fair market value, determined using the Black-Scholes option-pricing model.
	(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 and 2012, there was a loss recognized from the revaluation of the warrant liability of $311,062 and $148,364, respectively. For the three months ended June 30, 2013 and 2012, there was a gain recognized from the revaluation of the warrant liability of $221,149 and $222,546, respectively. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $337,244. For the three months ended September 30, 2012, there was a gain recognized from the revaluation of the warrant liability of $429,818.
	During the three months ended March 31, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,045,510. The Company accepted subscriptions, in the aggregate, for 5,394,013 shares of common stock and five year warrants to purchase 7,277,264 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $522,640 and issued five year fully vested warrants to purchase 539,401 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.
	During the three months ended June 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,641,501. The Company accepted subscriptions, in the aggregate, for 3,522,001 shares of common stock and five year warrants to purchase 5,283,003 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $314,173, accrued $32,500 at June 30, 2013 which was paid in July 2013 and issued five year fully vested warrants to purchase 352,200 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.
	During the three months ended September 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,613,037. The Company accepted subscriptions, in the aggregate, for 6,150,718 shares of common stock and five year warrants to purchase 9,226,077 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $564,686 and issued five year fully vested warrants to purchase 615,072 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

	During the three months ended September 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,687,500. The Company accepted subscriptions, in the aggregate, for 3,583,333 shares of common stock and five year warrants to purchase 5,375,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Maxim Group LLC served as placement agent for the offering. In connection with the offering, the Company paid $349,375 and issued five year fully vested warrants to purchase 358,333 shares of common stock with an exercise price of $1.00 to Maxim Group LLC, which represents 10% of the total number of shares of common stock sold to investors solicited by Maxim Group LLC.
	(d) In March and April 2010, the Company had an issuance of 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 and 2012, there was a loss recognized from the revaluation of the warrant liability of $446,698 and $114,800, respectively. For the three months ended June 30, 2013 and 2012, there was a gain recognized from the revaluation of the warrant liability of $399,057 and $229,599, respectively. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $275,279. For the three months ended September 30, 2012, there was a gain recognized from the revaluation of the warrant liability of $817,099.
	Dividends on the 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. In January 2013, the Company issued 61,022 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of January 15, 2013. At March 31, 2013, the Company recognized dividends of $21,921 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended March 31, 2013 there were 593,000 shares of the Company’s redeemable preferred stock that converted into 593,000 shares of the Company’s common stock. In April 2013, the Company issued 29,384 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of April 15, 2013. At June 30, 2013, the Company recognized dividends of $22,164 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended June 30, 2013 there were 403,520 shares of the Company’s redeemable preferred stock that converted into 403,520 shares of the Company’s common stock. In July 2013, the Company issued 34,598 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 15, 2013. At September 30, 2013, the Company recognized dividends of $10,586 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2013 there were 734,999 shares of the Company’s redeemable preferred stock that converted into 734,999 shares of the Company’s common stock.
	(e) On February 22, 2013, the Company entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of an aggregate of $2,550,000 of Units at a purchase price of $0.75 per Unit. Each Unit consists of one share of Series A 8% Convertible Preferred Stock, par value $.001 per share, and a warrant to purchase one and one-quarter shares of the Company’s common stock, par value $.001 per share (subject to adjustment) at an exercise price of $1.00 per whole share (subject to adjustment). The total Series A 8% Convertible Preferred Stock issued was 3,400,001 shares, and the total warrants were 4,250,000. The Company used the net proceeds of the private placement for working capital, FDA trials, securing licensing partnerships, and general corporate purposes.
	The Company determined that warrants issued in February, 2013 with the Series A 8% Convertible Preferred Stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The preferred stock was determined to have characteristics more akin to equity than debt. As a result, the conversion option was determined to be clearly and closely related to the preferred stock and therefore does not need to be bifurcated and classified as a liability. The proceeds received from the issuance of the preferred stock were first allocated to the fair value of the warrants with the remainder allocated to the preferred stock. The fair value of the preferred stock if converted on the date of issuance was greater than the value allocated to the preferred stock. As a result, a beneficial conversion amount was recorded upon issuance. The fair value of the warrants recorded from the February 2013 issuance was $1,297,950 resulting in a beneficial conversion amount of $1,025,950. The beneficial conversion has been recorded as a deemed dividend as of March 31, 2013 and is included in dividends on preferred stock on the consolidated statements of operations. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 there was a loss recognized from the revaluation of the warrant liability of $165,750. For the three months ended June 30, 2013 there was a gain recognized from the revaluation of the warrant liability of $289,000. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $290,275.
	Dividends on the Series A 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock although was required to pay the initial dividends due in cash. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. At March 31, 2013, the Company recognized dividends of $29,063 which are included in dividends on preferred stock on the consolidated statement of operations and were paid in April 2013. At June 30, 2013, the Company recognized dividends of $50,860 which are included in dividends on preferred stock on the consolidated statement of operations. In July 2013, the Company issued 79,401 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 15, 2013. At September 30, 2013, the Company recognized dividends of $28,104 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2013 there were 441,667 shares of the Company’s Series A 8% Convertible Preferred Stock that converted into 441,667 shares of the Company’s common stock.
	On June 23, 2013, our agreement with Lincoln Park Capital Fund, LLC expired. On July 22, 2013 the Company entered into a Purchase Agreement with Alpha Capital Anstalt pursuant to which the Company may, in the Company’s sole discretion, direct the purchase up to $30,000,000 of the Company’s common stock over the 30-month term of the Purchase Agreement. From time to time during the term of the Purchase Agreement, the Company may, in its sole discretion direct the purchase up to 100,000 shares of the Company’s common stock at a per share purchase price equal to the lesser of (i) the lowest sale price of the Company’s common stock reported on the OTCQB on the purchase date and (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 12 consecutive business days ending on the business day immediately preceding the purchase date. The Company may, under certain circumstances, at its discretion, increase the amount of common stock that it sells on each purchase date. The committed obligation under any single regular purchase shall not exceed $250,000, unless the parties mutually agree to increase the dollar amount of any regular purchase. In no event may Alpha Capital Anstalt purchase shares of the Company’s common stock for less than $0.75 per share. In consideration of entering into the Purchase Agreement and making the commitment to purchase the Purchase Shares, the Company issued 250,000 shares of the Company’s common stock to Alpha Capital Anstalt. Costs charged to operations for this commitment fee were $162,500. The Purchase Agreement may be terminated by the Company at any time, at its discretion, without cost to the Company.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
Stock-Based Compensation	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	5. Stock-Based Compensation
	One employee of the Company exercised 18,750 options at an exercise price of $0.32 per share of common stock for $6,000 and 25,000 options at an exercise price of $0.60 per share of common stock for $15,000 during the three months ended June 30, 2013. One former non-employee member of the board forfeited 25,000 stock options on May 29, 2013. On August 19, 2013, the Company issued 250,000 stock options to its re-elected members of the board. All of the stock options issued in 2013 vest on the date of grant and have an exercise price equal to the fair market price on the date of issuance. On May 14, 2012, the Company issued 50,000 stock options to a newly appointed member of the board. On June 28, 2012, the Company issued 200,000 stock options to its re-elected members of the board. All of the stock options issued in 2012 vest on the date of grant and have an exercise price equal to the fair market price on the date of issuance.
	The compensation cost relating to stock options issued in 2013 is measured based on the fair value of the stock options issued. For purposes of estimating the fair value of each stock option on the date of grant, the Company utilized the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock (as determined by reviewing its historical public market closing prices). Because the Company’s employee stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee and board member stock options. Included in the results of operations for both the three and nine months ended September 30, 2013 is $142,310 of stock-based compensation expense which relates to the fair value of stock options. Included in the results of operations for the three and nine months ended September 30, 2012 is $0 and $183,028, respectively, of stock-based compensation expense which relates to the fair value of stock options.

	The following is a summary of nonvested stock option activity for the nine months ended September 30, 2013:


		Number of Shares			Weighted Average
					Grant-Date
					Fair Value
	Nonvested at December 31, 2012		—		$	—
	Granted		250,000		$	0.57
	Vested		(250,000	)	$	0.57
	Canceled		—			—

	Nonvested at September 30, 2013		—		$	—
	As of September 30, 2013, there was no unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the Plan.

Related_Party_Transaction

Related Party Transaction	9 Months Ended
Related Party Transaction	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transaction	'
	6. Related Party Transaction
	The Company paid one non-employee member of the board $48,000 for consulting services performed as of September 30, 2013. The Company paid another non-employee member of the board $75,000 for consulting services performed as of September 30, 2013. The Company paid a third non-employee member of the board $75,000 for consulting services performed as of September 30, 2013.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
Fair Value of Financial Instruments	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	7. Fair Value of Financial Instruments
	The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:
	Level 1: Quoted market prices in active markets for identical assets or liabilities.
	Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.
	Level 3: Unobservable inputs that are not corroborated by market data.
	In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are measured and reported on a fair value basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. The fair value of certain of the Company’s financial instruments, including Cash and cash equivalents and Accounts payable, approximates the carrying value due to the relatively short maturity of such instruments. The fair value of derivative instruments is determined by management with the assistance of an independent third party valuation specialist. The warrant liability is a derivative instrument and is classified as Level 3. The Company used the Monte-Carlo Simulation model to estimate the fair value of the warrants. Significant assumptions used at March 31, 2013 for the 2010 warrants include a weighted average term of 2.0 years, a 5% probability that the warrant exercise price would be reset, volatility range of 58.0% to 59.1% and a risk free interest rate of 0.25%. Significant assumptions used at June 30, 2013 for the 2010 warrants include a weighted average term of 1.7 years, a 5% probability that the warrant exercise price would be reset, volatility range of 55.7% to 56.5% and a risk free interest rate of 0.36%. Significant assumptions used at September 30, 2013 for the 2010 warrants include a weighted average term of 1.5 years, a 5% probability that the warrant exercise price would be reset, volatility range of 59.0% to 59.4% and a risk free interest rate of 0.33%. Significant assumptions used at March 31, 2013 for the 2011 warrants include a weighted average term of 2.8 years, a 5% probability that the warrant exercise price would be reset, volatility range of 58.0% to 59.1% and a risk free interest rate of 0.25%. Significant assumptions used at June 30, 2013 for the 2011 warrants include a weighted average term of 2.5 years, a 5% probability that the warrant exercise price would be reset, volatility of 59.1% and a risk free interest rate of 0.66%. Significant assumptions used at September 30, 2013 for the 2011 warrants include a weighted average term of 2.3 years, a 5% probability that the warrant exercise price would be reset, volatility of 58.6% and a risk free interest rate range of 0.33% to 0.63%. Significant assumptions used at March 31, 2013 for the 2013 warrants include a weighted average term of 4.9 years, a 5% probability that the warrant exercise price would be reset, volatility range of 58.0% to 66.7% and a risk free interest rate range of 0.25% to 0.77%. Significant assumptions used at June 30, 2013 for the 2013 warrants include a weighted average term of 4.7 years, a 5% probability that the warrant exercise price would be reset, volatility of 64.6% and a risk free interest rate of 1.41%. Significant assumptions used at September 30, 2013 for the 2013 warrants include a weighted average term of 4.4 years, a 5% probability that the warrant exercise price would be reset, volatility of 64.3% and a risk free interest rate of 1.39%.

	The warrant liability measured at fair value on a recurring basis is as follows:


		Total		Level 1		Level 2		Level 3
	Derivative instruments:
	Warrant liability at September 30, 2013	$	3,514,622	$	—	$	—	$	3,514,622
	Warrant liability at December 31, 2012	$	1,299,570	$	—	$	—	$	1,299,570
	A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2013 to September 30, 2013 follows:


	Balance at January 1, 2013	$	1,299,570
	Issuance of warrants		1,297,950
	Net loss included in earnings		917,102
	Exercise of warrants		—

	Balance at September 30, 2013	$	3,514,622

Equity_Transactions_Policies

Equity Transactions (Policies)	9 Months Ended
Equity Transactions (Policies)	Sep. 30, 2013
Text Block [Abstract]	'
Derivatives Policies	'
	(c) The Company determined that warrants issued January 13, 2011 and referred to as Series A Warrants and Series C Warrants should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 and 2012, there was a loss recognized from the revaluation of the warrant liability of $311,062 and $148,364, respectively. For the three months ended June 30, 2013 and 2012, there was a gain recognized from the revaluation of the warrant liability of $221,149 and $222,546, respectively. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $337,244. For the three months ended September 30, 2012, there was a gain recognized from the revaluation of the warrant liability of $429,818.
	During the three months ended March 31, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,045,510. The Company accepted subscriptions, in the aggregate, for 5,394,013 shares of common stock, and five year warrants to purchase 7,277,264 shares of common stock. Investors received five year fully vested warrants to purchase up to 100% to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $522,640 and issued five year fully vested warrants to purchase 539,401 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.
	During the three months ended June 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,641,501. The Company accepted subscriptions, in the aggregate, for 3,522,001 shares of common stock, and five year warrants to purchase 5,283,003 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $314,173, accrued $32,500 at June 30, 2013 which was paid in July 2013 and issued five year fully vested warrants to purchase 352,200 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.
	During the three months ended September 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $4,613,037. The Company accepted subscriptions, in the aggregate, for 6,150,718 shares of common stock, and five year warrants to purchase 9,226,077 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Network 1 Financial Securities, Inc. served as placement agent for the offering. In connection with the offering, the Company paid $564,686 and issued five year fully vested warrants to purchase 615,072 shares of common stock with an exercise price of $1.00 to Network 1 Financial Securities, Inc., which represents 10% of the total number of shares of common stock sold to investors solicited by Network 1 Financial Securities, Inc.

	During the three months ended September 30, 2013 the Company completed a private offering of common stock and warrants to accredited investors for gross proceeds of $2,687,500. The Company accepted subscriptions, in the aggregate, for 3,583,333 shares of common stock, and five year warrants to purchase 5,375,000 shares of common stock. Investors received five year fully vested warrants to purchase up to 150% of the number of shares purchased by the investors in the offering. The warrants have an exercise price of $1.00 per share. The purchase price for each share of common stock together with the warrants was $0.75. The Company used the proceeds for working capital and other general corporate purposes. Maxim Group LLC served as placement agent for the offering. In connection with the offering, the Company paid $349,375 and issued five year fully vested warrants to purchase 358,333 shares of common stock with an exercise price of $1.00 to Maxim Group LLC, which represents 10% of the total number of shares of common stock sold to investors solicited by Maxim Group LLC.
	(d) In March and April 2010, the Company had an issuance of 8% Convertible Preferred Stock with warrants. The Company determined that warrants issued with the 8% convertible preferred stock should be classified as liabilities in accordance with ASC 815 because the warrants in question contain exercise price reset features that require the exercise price of the warrants be adjusted if the Company issues certain other equity related instruments at a lower price per share. The value of the warrant liability was determined based on the Monte-Carlo Simulation model at the date the warrants were issued. The warrant liability is then revalued at each subsequent quarter. For the three months ended March 31, 2013 and 2012, there was a loss recognized from the revaluation of the warrant liability of $446,698 and $114,800, respectively. For the three months ended June 30, 2013 and 2012, there was a gain recognized from the revaluation of the warrant liability of $399,057 and $229,599, respectively. For the three months ended September 30, 2013 there was a loss recognized from the revaluation of the warrant liability of $275,279. For the three months ended September 30, 2012, there was a gain recognized from the revaluation of the warrant liability of $817,099.
	Dividends on the 8% Convertible Preferred Stock accrue at an annual rate of 8% of the original issue price and are payable in either cash or common stock. If the dividend is paid in common stock, the number of shares of common stock will equal the quotient of the amount of cash dividends divided by the market price of the stock on the dividend payment date. The dividends are payable quarterly on the 15th day after the quarter-end. The Company anticipates paying the dividends in common stock. The Company has a deficit and, as a result, the dividends are recorded against additional paid-in capital. In January 2013, the Company issued 61,022 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of January 15, 2013. At March 31, 2013, the Company recognized dividends of $21,921 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended March 31, 2013 there were 593,000 shares of the Company’s redeemable preferred stock that converted into 593,000 shares of the Company’s common stock. In April 2013, the Company issued 29,384 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of April 15, 2013. At June 30, 2013, the Company recognized dividends of $22,164 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended June 30, 2013 there were 403,520 shares of the Company’s redeemable preferred stock that converted into 403,520 shares of the Company’s common stock. In July 2013, the Company issued 34,598 shares of common stock in dividends on preferred stock in lieu of cash dividends due as of July 15, 2013. At September 30, 2013, the Company recognized dividends of $10,586 which are included in dividends on preferred stock on the consolidated statement of operations. During the three months ended September 30, 2013 there were 734,999 shares of the Company’s redeemable preferred stock that converted into 734,999 shares of the Company’s common stock.

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
Stock-Based Compensation (Tables)	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Nonvested Stock Option Activity	'
	The following is a summary of nonvested stock option activity for the nine months ended September 30, 2013:


		Number of Shares			Weighted Average
					Grant-Date
					Fair Value
	Nonvested at December 31, 2012		—		$	—
	Granted		250,000		$	0.57
	Vested		(250,000	)	$	0.57
	Canceled		—			—

	Nonvested at September 30, 2013		—		$	—

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	9 Months Ended
Fair Value of Financial Instruments (Tables)	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Warrant Liability Measured at Fair Value on a Recurring Basis	'
	The warrant liability measured at fair value on a recurring basis is as follows:


		Total		Level 1		Level 2		Level 3
	Derivative instruments:
	Warrant liability at September 30, 2013	$	3,514,622	$	—	$	—	$	3,514,622
	Warrant liability at December 31, 2012	$	1,299,570	$	—	$	—	$	1,299,570
Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis	'
	A reconciliation of the warranty liability measured at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) from January 1, 2013 to September 30, 2013 follows:


	Balance at January 1, 2013	$	1,299,570
	Issuance of warrants		1,297,950
	Net loss included in earnings		917,102
	Exercise of warrants		—

	Balance at September 30, 2013	$	3,514,622

Recapitalization_and_Merger_Ad

Recapitalization and Merger - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
Common stock shares issued	6,680,000

Basic_and_Diluted_Loss_Per_Com1

Basic and Diluted Loss Per Common Share - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Common shares excluded from the calculation	66,238,507	26,042,116
Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Common shares excluded from the calculation	15,322,206	15,140,956
8% Convertible Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Common shares excluded from the calculation	3,705,000	2,941,665

Equity_Transactions_Additional

Equity Transactions - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

140 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

Jul. 22, 2013

Feb. 28, 2013

Jan. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Feb. 22, 2013

Dec. 31, 2012

Mar. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Feb. 22, 2013

Feb. 28, 2013

Sep. 30, 2013

Feb. 22, 2013

Jul. 31, 2013

Apr. 30, 2010

Mar. 31, 2010

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Jul. 31, 2013

Apr. 30, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Minimum [Member]

Maximum [Member]

Network 1 Financial Securities [Member]

Maxim Group Llc [Member]

Common Stock [Member]

Series A 8% Convertible Preferred Stock [Member]

8% Convertible Preferred Stock [Member]

Warrants [Member]

Redeemable Preferred Stock [Member]

Warrant 1 [Member]

Class of Stock [Line Items]

Issuance of common stock to consultants

75,000

225,000

75,000

175,000

Consulting costs charges

$51,250

$49,500

$48,750

$184,750

$64,500

$160,000

Issuance of warrants to consultants

442,000

2,605,000

1,924,973

1,732,135

454,500

1,003,000

Consulting costs charges related to warrants

186,223

931,655

409,640

721,753

183,908

475,668

Warrants forfeited

136,500

1,051,500

859,833

122,833

4,368,644

1,500

Gain Loss on Revaluation of Warrants Liability

337,244

221,149

311,062

429,818

222,546

148,364

275,279

399,057

446,698

817,099

229,599

114,800

290,275

289,000

165,750

Gross proceeds from private offering of common stock and warrants to accredited investors

4,613,037

2,641,501

4,045,510

2,687,500

Company accepted subscriptions, in the aggregate

6,150,718

3,522,001

5,394,013

3,583,333

Period of warrants to purchase common stock

'5 years

Common Stock to be Issued on Exercise of Warrant

9,226,077

5,283,003

7,277,264

9,226,077

615,072

352,200

539,401

358,333

Investors received five year warrants

100.00%

150.00%

Exercise price of common stock

Purchase price of common stock

$0.75

Payment of fully vested warrants

564,686

314,173

522,640

349,375

Percentage of Aggregate Shares Called by Warrant

10.00%

Purchase price of common stock with warrants

$0.75

Warrant accrued

32,500

Convertible preferred stock

8.00%

Common stock shares issued in lieu of cash dividends for Preferred stock

61,022

79,401

Dividends on preferred stock

38,690

43,884

1,188,648

145,709

12,026,710

10,586

22,164

21,921

28,104

50,860

29,063

Converted preferred stock

441,667

734,999

403,520

593,000

Preferred stock converted into shares

441,667

734,999

403,520

593,000

34,598

29,384

Issuance and sale in a private placement accredited to investors

2,550,000

8% convertible preferred stock, par value

$0.00

Preferred stock, par value

$0.00

Common stock, par value

$0.00

Preferred stock, shares issued

2,958,334

3,400,001

746,666

2,478,185

Purchase price of preferred stock with warrants

4,250,000

Common stock unit fair value warrants recorded on issuance

1,297,950

Common stock unit beneficial conversion amount

1,025,950

Purchase of common stock

30,000,000

Term of purchase Agreement

'30 months

Purchase of common stock

100,000

Regular purchase limit

250,000

Less than the per share value of common stock

$0.75

Issue of common stock

250,000

Costs charged to operations for commitment fee

$162,500

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended		1 Months Ended			3 Months Ended
	31-May-13	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Aug. 31, 2013	Jun. 30, 2012	31-May-12	Jun. 30, 2013	Jun. 30, 2013
	31-May-13	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Re Elected Board Member [Member]	Re Elected Board Member [Member]	Newly Appointed Board Member [Member]	Options Exercised Price One [Member]	Options Exercised Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Stock Options Exercised Shares	'	'	'	'	'	'	'	'	18,750	25,000
Stock Options Exercise at Exercise Price Per Share	'	'	'	'	'	'	'	'	$0.32	$0.60
Stock Options Exercise Value	'	'	'	'	'	'	'	'	$6,000	$15,000
Stock option forfeited	25,000	'	'	'	'	'	'	'	'	'
Stock option issued	'	'	'	250,000	'	250,000	200,000	50,000	'	'
Stock-based compensation expense	'	142,310	0	142,310	183,028	'	'	'	'	'
Unrecognized stock-based compensation expense	'	$0	'	$0	'	'	'	'	'	'

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Nonvested Stock Option Activity (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Number of Shares, Nonvested at December 31, 2012	'
Number of Shares, Granted	250,000
Number of Shares, Vested	-250,000
Number of Shares, Canceled	'
Number of Shares, Nonvested at September 30, 2013	'
Weighted Average Grant-Date Fair Value, Nonvested at December 31, 2012	'
Weighted Average Grant-Date Fair Value, Granted	$0.57
Weighted Average Grant-Date Fair Value, Vested	$0.57
Weighted Average Grant-Date Fair Value, Canceled	'
Weighted Average Grant-Date Fair Value, Nonvested at September 30, 2013	'

Related_Party_Transaction_Addi

Related Party Transaction - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
	NonEmployee
Subsequent Event [Line Items]	'
Payment for consulting services	$48,000
Number of non employee to whom consulting services paid	1
Non Employee [Member]	'
Subsequent Event [Line Items]	'
Payment for consulting services to another non-employee	75,000
Third Non Employee [Member]	'
Subsequent Event [Line Items]	'
Payment for consulting services to another non-employee	$75,000

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Additional Information (Detail)	3 Months Ended	6 Months Ended	9 Months Ended
	Mar. 31, 2013	Jun. 30, 2013	Sep. 30, 2013
2010 Warrants [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Weighted average term	'2 years	'1 year 8 months 12 days	'1 year 6 months
Warrant exercise price probability	5.00%	5.00%	5.00%
Risk free interest rate	0.25%	0.36%	0.33%
2010 Warrants [Member] \| Maximum [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Percentage of volatility	59.10%	56.50%	59.40%
2010 Warrants [Member] \| Minimum [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Percentage of volatility	58.00%	55.70%	59.00%
2011 Warrants [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Weighted average term	'2 years 9 months 18 days	'2 years 6 months	'2 years 3 months 18 days
Warrant exercise price probability	5.00%	5.00%	5.00%
2011 Warrants [Member] \| Maximum [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Risk free interest rate	0.25%	0.66%	0.63%
Percentage of volatility	59.10%	59.10%	58.60%
2011 Warrants [Member] \| Minimum [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Risk free interest rate	'	'	0.33%
Percentage of volatility	58.00%	'	'
2013 Warrants [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Weighted average term	'4 years 10 months 24 days	'4 years 8 months 12 days	'4 years 4 months 24 days
Warrant exercise price probability	5.00%	5.00%	5.00%
2013 Warrants [Member] \| Maximum [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Risk free interest rate	0.77%	1.41%	1.39%
Percentage of volatility	66.70%	64.60%	64.30%
2013 Warrants [Member] \| Minimum [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Risk free interest rate	0.25%	'	'
Percentage of volatility	58.00%	'	'

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Warrant Liability Measured at Fair Value on a Recurring Basis (Detail) (Recurring [Member], Warrants [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
Derivative instruments:	'	'
Warrant liability	$3,514,622	$1,299,570
Level 1 [Member]	'	'
Derivative instruments:	'	'
Warrant liability	'	'
Level 2 [Member]	'	'
Derivative instruments:	'	'
Warrant liability	'	'
Level 3 [Member]	'	'
Derivative instruments:	'	'
Warrant liability	$3,514,622	$1,299,570

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Reconciliation of the Warranty Liability Measured at Fair Value on a Recurring Basis (Detail) (Recurring [Member], Level 3 [Member], Warrants [Member], USD $)	9 Months Ended
	Sep. 30, 2013
Recurring [Member] \| Level 3 [Member] \| Warrants [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Beginning Balance	$1,299,570
Issuance of warrants	1,297,950
Net loss included in earnings	917,102
Exercise of warrants	'
Ending Balance	$3,514,622